ExThera Medical Corporation, a Berkeley, Calif.-based medical device company, completed a $3.75m first closing of its $7m convertible note offering.
The company intends to use the funds to complete the first clinical trial and commercialize its Seraph® Microbind® Affinity Blood Filter.
Led Robert S. Ward, PhD, President and CEO, ExThera Medical is advancing Seraph®, a biomimetic therapeutic device that aims to remove an extremely broad range of viruses, bacteria, fungi and toxins from whole blood. It can be an adjunct to anti-infective drugs by reducing the load and duration of infection, potentially preventing complications and the systemic inflammatory response that leads to organ failure. When no effective drugs are available Seraph may help patients recover by supplementing their own immune systems.
FinSMEs
06/10/2014